SIK ATAK GEÇİREN KOAH HASTALARINDA KÜÇÜK HAVA YOLLARININ ÖNEMİ

Yıl 2014, Cilt: 28 Sayı: 1, 15 - 22, 01.05.2014

Yelda Varol Ceyda Anar Levent Usta Günseli Balcı Rıfat Özacar

Öz

KOAH alevlenmeleri, hastalığın seyrini etkileyen önemli bir etmendir. Klinik çalışmalar bazı hastaların FEV1 düzeyinden bağımsız daha sık alevlenme geçirdiğini göstermiş ve sık alevlenme geçiren bir alt grup tanımlanmıştır. Küçük hava yolu hasarı KOAH hastalık progresyonunda önemli bir rol oynar ancak küçük hava yolu hasarı ile KOAH alevlenmeleri arasındaki ilişki netlik kazanmamıştır. Çalışmamızda sık alevlenme geçiren KOAH fenotipinin küçük hava yolu hasarı açısından ve sık alevlenme geçirmeyen alt gruptan farklılığı araştırılmıştır. Çalışmaya Nisan 2011- Şubat 2012 arasında 96 stabil KOAH hastası alındı. Son 1 yıl içinde 2 ve üzerinde atak geçiren hastalar sık atak geçiren grup, son 1 yıl içinde 1 ve altında atak geçiren hastalar sık atak geçirmeyen grup olarak kabul edildi. Sık atak geçiren 51 hastanın ortalama FEV 1'i 880ml (%34), FVC'si 1500 ml (%45) FEV1/FVC: 60, FEF25- 75 değeri 549 ml (%17) saptandı. Sık atak geçirmeyen 45 hastanın ortalama FEV 1'i 1210ml (%44), FVCsi 1780 ml (%53) FEV1/FVC: 65, FEF25-75 değeri 750 ml (%25) saptanmıştır. Sık atak geçiren ve geçirmeyen hastaların FEF 25-75 değeri (p=0.009), FEF 25-75 % (p= 0.000), FEV1 ml (p=0.016), FEV1 % (p=0.007), FEV1/FVC (p=0.021) değeri arasında istatistiksel anlamlı fark saptanmıştır. Son 1 yıl için de KOAH akut atak nedeniyle hastaneye yatan hastalar ile yatmayan hastalar karşılaştırıldığında yalnızca FEF25-75 ml (p=0.015) ve FEF 25-75 % (p=0.014) değerleri arasında istatistiksel anlamlı fark saptanmıştır. Sık atak geçiren ve hastane yatışı gerektiren atak geçiren KOAH hastalarının FEF25-75 değerleri istatistiksel anlamlı daha düşük bulunmuştur. Küçük hava yolu obstrüksiyonu ve atak sıklığını araştıran klinik çalışmalara gereksinim duyulmaktadır.

Anahtar Kelimeler

KOAH, atak, küçük hava yolları, FEF25-75

IMPAIRMENT OF SMALL AIRWAYS IN COPD PATIENTS WITH FREQUENT EXACERBATIONS

Öz

COPD exacerbations are important and affects the course of the disease. Clinical trials showed that a subgroup of COPD patients had more exacerbations independent from their FEV1 values and thus a frequent exacerbation subgroup was defined. Small-airway damage has a role for the disease progression of COPD, but the exact relationship between small-airway damage and COPD exacerbations is not entirely clarified. In our study, we investigated the COPD patients who had frequent exacerbations in terms of small airway damage and their difference from patients who had not frequent exacerbations. 96 stable COPD patients between April 2011 and February 2012 were included in our study. If the patients had two or more exacerbation in the last year, they were defined as frequent exacerbators, if not they were defined as unfrequent exacerbators. The mean FEV1 value of 51 frequent exacerbator was 880ml(34%). Their mean FVC was 1500 ml(45%), mean FEV1/FVC was 60 and mean FEF25-75 was 549 ml(17%). The mean FEV1, FVC, FEV1/FVC and FEF25- 75 values of 45 unfrequent exacerbators were found as 1210ml(44%), 1780 ml(53%), 65 and 750 ml(25%) respectively. When we compared frequent and unfrequent exacerbators, statistical significance was found in FEF 25-75(p=0.009), FEF 25-75 %(p= 0.000), FEV1 ml(p=0.016), FEV1 %(p=0.007), FEV1/FVC(p=0.021) values. In addition, we found statistical significance only in FEF25-75 ml(p=0.015) and FEF 25-75 %(p=0.014) values between patients who were hospitalized in the last year because of COPD exacerbation or not. The FEF25-75 values were found significantly low in frequent exacerbators and who hospitalized due to COPD exacerbations. However, additional comprehensive randomized trials dealing with small-airway obstruction and exacerbation frequency are essential.

Anahtar Kelimeler

COPD, exacerbations, small airways, FEF25–75

Kaynakça

• 1. Erdinç E, Polatlı M, Kocabaş A,Yıldırım N, Gürgün A, Saryal S, Köktürk N, Yarkın T, Kıyan E, Uzaslan EK, Sevinç C, Çöplü L, Sayıner A, Günen H, Karakurt S, Ergün P, Erdinç M, Şen E, Umut S, Yılmaz V, Çımrın AH, Demir T. KOAH Tanı ve Tedavi Uzlaşı Raporu 2010. Türk Toraks Dergisi 2010; 11: 5-6.
• 2. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696–704.
• 3. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702.
• 4. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
• 5. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 2002; 96: 700–8.
• 6. Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. Thorax 2006; 61: 164–8.
• 7. Marin JM, Carrizo SJ, Casanova C, MartinezCamblor P, Soriano JB, Agusti AG, Celli BR. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009; 103: 373–8.
• 8. Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007; 30: 1124–30.
• 9. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975–82.
• 10. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20–8.
• 11. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32: 53–60.
• 12. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224–38.
• 13. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003; 41: 46–53.
• 14. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF, COSMIC study group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133: 350–7.
• 15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverly P, Rennard S, Wouters EF, Wedzigha JA. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
• 16. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
• 17. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L,Cherniak RM, Rogers RM, Sciurba FC, Coxson HQ, Pare PD. The Nature of Small-airway Obstruction in Chronic Obstructive Pulmonary Disease. N Engl J Med 2004; 350: 2645-53.
• 18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of cronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
• 19. GOLD executive committee. Global strategy for diagnosis, management and prevention of COPD, [updated 2011]. Avaliable from: http://www.golcopd.com.
• 20. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2- agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3 CD001104.
• 21. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;2 CD002876.
• 22. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 2 CD002991.
• 23. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalisations in the United States, 1979- 2001. Chest 2005; 128: 2005-11.
• 24. Siddiqui S, Usmani OS. Small airways, big challenge: measuring the unseen? Nature Medicine 2012; 11: 1619-21.
• 25. Nagai A, West WW, Paul JL, Thurlbeck WM. The National Institutes of Health Intermittent Positive Pressure Breathing trial: pathology studies. Am Rev Respir Dis 1985; 132: 932-45.
• 26. Incorvaia C, Riariosforza GG, Pravettoni C, Yacoub MR, Frati F. Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. International Journal of COPD 2008; 3: 123-6.